stockrowCandel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.
- EPS
- −477.8%
- Free cash flow
- −93.4%
- Total debt
- +525.8%
Quarter to June 2026, against a year earlier
Follow CADL
Alert me
Candel Therapeutics, Inc. (CADL) EV/Sales
As of 6 November 2026, Candel Therapeutics, Inc. (CADL) trades at a EV/Sales of 3,940×. Over the past ten years it has ranged from −106× (December 2022) to 6,958× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 18.2× | (96.55%) |
| FY2021 | 528× | 11.46% |
| FY2020 | 473× | 0.00% |
| FY2019 | 473× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 18.2× | (93.45%) |
| Sep 2022 | 278× | 25.71% |
| Jun 2022 | 221× | (61.97%) |
| Mar 2022 | 581× | 10.15% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | 1.7× |
| GERN Geron Corporation compare | 2.6× |
| ZVRA Zevra Therapeutics, Inc. compare | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| DBVT DBV Technologies S.A. compare | 211× |
| DSGN Design Therapeutics, Inc. compare | 1,919× |
| CADL Candel Therapeutics, Inc. | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)